The integrative management of treatment-resistant depression: a comprehensive review and perspectives.
| Data(s) |
01/03/2014
|
|---|---|
| Resumo |
Major depressive disorder is a prevalent and disabling illness. Notwithstanding numerous advances in the pharmacological treatment of depression, approximately 70% of patients do not remit after first-line antidepressant treatment. |
| Identificador | |
| Idioma(s) |
eng |
| Publicador |
Karger |
| Relação |
http://dro.deakin.edu.au/eserv/DU:30069429/berk-integrativemanagement-2014.pdf http://www.dx.doi.org/10.1159/000357500 http://www.ncbi.nlm.nih.gov/pubmed/24458008 |
| Direitos |
2014, Karger |
| Palavras-Chave | #Atypical antipsychotics #Augmentation #Combination #Lithium #Switching #Treatment-resistant depression #Triiodothyronine #SEROTONIN REUPTAKE INHIBITORS #PLACEBO-CONTROLLED TRIAL #ASTERISK-D REPORT #RANDOMIZED CONTROLLED-TRIAL #ATYPICAL ANTIPSYCHOTIC MEDICATIONS #VENLAFAXINE EXTENDED-RELEASE #SSRI-REFRACTORY DEPRESSION #D-ASPARTATE ANTAGONIST #DOUBLE-BLIND #MAJOR DEPRESSION |
| Tipo |
Journal Article |
